Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex

Neuro-Oncology

Volumn 12, Issue 3, 2010, Pages 265-273

  De Groot, Marjolein ^a,b   Toering, Sjoukje T ^a   Boer, Karin ^b   Spliet, Wim G M ^c   Heimans, Jan J ^a   Aronica, Eleonora ^b,d   Reijneveld, Jaap C ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

Brain tumors; Epilepsy; Human; Peritumoral cortex; Synaptic vesicle protein

Indexed keywords

BINDING PROTEIN; ETIRACETAM; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; NERVE PROTEIN; SV2A PROTEIN, HUMAN;

ADULT; ARTICLE; BRAIN CORTEX; BRAIN TUMOR; CONTROLLED STUDY; EPILEPSY; EPILEPTOGENESIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL; PERITUMORAL CORTEX; PROTEIN EXPRESSION; ADOLESCENT; BIOSYNTHESIS; METABOLISM; MIDDLE AGED; WESTERN BLOTTING;

ADOLESCENT; ADULT; BLOTTING, WESTERN; BRAIN NEOPLASMS; EPILEPSY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; YOUNG ADULT;

EID: 77952315692     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop028     Document Type: Article

References (36)

1. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421-430.
2. Aronica E, Leenstra S, van Veelen CW, et al. Glioneuronal tumors and medically intractable epilepsy: a clinical study with long-term follow-up of seizure outcome after surgery. Epilepsy Res. 2001;43(3):179-191.
3. Blumcke I, Wiestler OD. Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol. 2002;61(7) :575-584.
4. Klein M, Engelberts NH, van der Ploeg HM, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life 3. Ann Neurol. 2003;54(4):514-520.
5. Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol. 2002;14(3):299-307.
6. Maschio M, Dinapoli L, Zarabia A, Jandolo B. issues related to the pharmacological management of patients with brain tumours and epilepsy. Funct Neurol. 2006;21(1):15-19.
7. Aronica E, Redeker S, Boer K, et al. Inhibitory networks in epilepsy-associated gangliogliomas and in the perilesional epileptic cortex. Epilepsy Res. 2007;74(1):33-44.
8. Baayen JC, de Jongh A, Stam CJ, et al. Localization of slow wave activity in patients with tumor-associated epilepsy. Brain Topogr. 2003;16(2): 85-93.
9. Kohling R, Senner V, Paulus W, Speckmann EJ. Epileptiform activity preferentially arises outside tumor Invasion zone in glioma xenotransplants. Neurobiol. Dis. 2006;22(1):64-75.
10. Wolf HK, Birkholz T, Wellmer J, Biumcke I, Pietsch T, Wiestler OD. Neurochemical profile of glioneuronal lesions from patients with pharmacoresistant focal epilepsies. J Neuropathol Exp Neurol. 1995;54(5): 689-697.
11. Aronica E, Yankaya B, Jansen GH, et al. Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumors from patients with intractable epilepsy. Neuropathol. Appl. Neurobiol. 2001;27:1-16.
12. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101(26):9861-9866.
13. Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol. 2006;536(1-2):102-108.
14. Bennett B, Matagne A, Michel P, et al. Seletracetam (UCB 44212). Neurotherapeutics. 2007;4(1):117-122.
15. von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics. 2007;4(1):84-87.
16. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007;4(1):18-61.
17. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol. 2006;78(1):99-102.
18. Wagner GL, Wilms EB, van Donselaar CA, Vecht C. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure. 2003;12(8):585-586.
19. Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994;14(9):5223-5235.
20. 2+ regulators in neurotransmitter release. Neuron. 1999;24(4):1003-1016.
21. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J. Neurosci. 2006;26(4):1303-1313.
22. Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA. 1999;96(26):15268-15273.
23. Gorter JA, Van Vliet E, Aronica E, et al. Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci. 2006;26(43):11083-11110.
24. van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia. 2009;50(3):422-433.
25. Stahl SM. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry. 2004;65(9): 1162-1163.
26. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC; 2007.
27. Ravizza T, Boer K, Redeker S, et al. The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis. 2006;24(1):128-143.
28. Aronica E, Boer K, van Vliet EA, et al. Complement activation in experimental and human temporal lobe epilepsy. Neurobiol Dis. 2007;26(3): 497-511.
29. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid [published erratum appears in Anal Biochem 1987;163(1):279]. Anal Biochem. 1985;150(1): 76-85.
30. Toering ST, Boer K, de Groot M, et al. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers [published online ahead of print, 2009]. Epilepsia.
31. Wharton SB, Chan KK, Whittle IR. Microtubule-assoclated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas. J Clin Neurosci. 2002;9(2):165-169.
32. Wharton SB, Chan KK, Hamilton FA, Anderson JR. Expression of neuronal markers in oligodendrogliomas: an immunohistochemical study. Neuropathol Appl Neurobiol. 1998;24(4):302-308.
33. Wolf HK, Buslei R, Blumcke I, Wiestler OD, Pietsch T. Neural antigens in oligodendrogliomas and dysembryoplastic neuroepithelial tumors. Acta Neuropathol (Berl). 1997;94(5):436-443.
34. Patel U, Pinto RS, Miller DC, et al. MR of spinal cord ganglioglioma [see comment). Am J Neuroradiol. 1998;19(5):879-887.
35. Quinn B. Synaptophysin staining in normal brain: importance for diagnosis of ganglioglioma. Am J Surg Pathol. 1998;22(5): 550-556.
36. Miller DC, Koslow M, Budzllovich GN, Burstein DE. Synaptophysin: a sensitive and specific marker for ganglion cells in central nervous system neoplasms. Human Pathol. 1990;21(3):271-276. (Pubitemid 20081226)